Dielectrophoresis-based microfluidic platforms for cancer diagnostics

Jun Yuan Chan, Aminuddin Bin Ahmad Kayani, Mohd Anuar Md Ali, Chee Kuang Kok, Burhanuddin Yeop Majlis, Susan Ling Ling Hoe, Marini Marzuki, Alan Soo Beng Khoo, Kostya Ostrikov, Md Ataur Rahman, Sharath Sriram

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The recent advancement of dielectrophoresis (DEP)-enabled microfluidic platforms is opening new opportunities for potential use in cancer disease diagnostics. DEP is advantageous because of its specificity, low cost, small sample volume requirement, and tuneable property for microfluidic platforms. These intrinsic advantages have made it especially suitable for developing microfluidic cancer diagnostic platforms. This review focuses on a comprehensive analysis of the recent developments of DEP enabled microfluidic platforms sorted according to the target cancer cell. Each study is critically analyzed, and the features of each platform, the performance, added functionality for clinical use, and the types of samples, used are discussed. We address the novelty of the techniques, strategies, and design configuration used in improving on existing technologies or previous studies. A summary of comparing the developmental extent of each study is made, and we conclude with a treatment of future trends and a brief summary.

Original languageEnglish
Article number011503
JournalBiomicrofluidics
Volume12
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Microfluidics
Electrophoresis
platforms
cancer
Neoplasms
Cells
Technology
Costs and Cost Analysis
trends
requirements
Costs
configurations

ASJC Scopus subject areas

  • Molecular Biology
  • Materials Science(all)
  • Genetics
  • Condensed Matter Physics
  • Physical and Theoretical Chemistry

Cite this

Chan, J. Y., Ahmad Kayani, A. B., Md Ali, M. A., Kok, C. K., Yeop Majlis, B., Hoe, S. L. L., ... Sriram, S. (2018). Dielectrophoresis-based microfluidic platforms for cancer diagnostics. Biomicrofluidics, 12(1), [011503]. https://doi.org/10.1063/1.5010158

Dielectrophoresis-based microfluidic platforms for cancer diagnostics. / Chan, Jun Yuan; Ahmad Kayani, Aminuddin Bin; Md Ali, Mohd Anuar; Kok, Chee Kuang; Yeop Majlis, Burhanuddin; Hoe, Susan Ling Ling; Marzuki, Marini; Khoo, Alan Soo Beng; Ostrikov, Kostya; Ataur Rahman, Md; Sriram, Sharath.

In: Biomicrofluidics, Vol. 12, No. 1, 011503, 01.01.2018.

Research output: Contribution to journalArticle

Chan, JY, Ahmad Kayani, AB, Md Ali, MA, Kok, CK, Yeop Majlis, B, Hoe, SLL, Marzuki, M, Khoo, ASB, Ostrikov, K, Ataur Rahman, M & Sriram, S 2018, 'Dielectrophoresis-based microfluidic platforms for cancer diagnostics', Biomicrofluidics, vol. 12, no. 1, 011503. https://doi.org/10.1063/1.5010158
Chan JY, Ahmad Kayani AB, Md Ali MA, Kok CK, Yeop Majlis B, Hoe SLL et al. Dielectrophoresis-based microfluidic platforms for cancer diagnostics. Biomicrofluidics. 2018 Jan 1;12(1). 011503. https://doi.org/10.1063/1.5010158
Chan, Jun Yuan ; Ahmad Kayani, Aminuddin Bin ; Md Ali, Mohd Anuar ; Kok, Chee Kuang ; Yeop Majlis, Burhanuddin ; Hoe, Susan Ling Ling ; Marzuki, Marini ; Khoo, Alan Soo Beng ; Ostrikov, Kostya ; Ataur Rahman, Md ; Sriram, Sharath. / Dielectrophoresis-based microfluidic platforms for cancer diagnostics. In: Biomicrofluidics. 2018 ; Vol. 12, No. 1.
@article{fdc266a8d623450db6ea4933bf6d6a2b,
title = "Dielectrophoresis-based microfluidic platforms for cancer diagnostics",
abstract = "The recent advancement of dielectrophoresis (DEP)-enabled microfluidic platforms is opening new opportunities for potential use in cancer disease diagnostics. DEP is advantageous because of its specificity, low cost, small sample volume requirement, and tuneable property for microfluidic platforms. These intrinsic advantages have made it especially suitable for developing microfluidic cancer diagnostic platforms. This review focuses on a comprehensive analysis of the recent developments of DEP enabled microfluidic platforms sorted according to the target cancer cell. Each study is critically analyzed, and the features of each platform, the performance, added functionality for clinical use, and the types of samples, used are discussed. We address the novelty of the techniques, strategies, and design configuration used in improving on existing technologies or previous studies. A summary of comparing the developmental extent of each study is made, and we conclude with a treatment of future trends and a brief summary.",
author = "Chan, {Jun Yuan} and {Ahmad Kayani}, {Aminuddin Bin} and {Md Ali}, {Mohd Anuar} and Kok, {Chee Kuang} and {Yeop Majlis}, Burhanuddin and Hoe, {Susan Ling Ling} and Marini Marzuki and Khoo, {Alan Soo Beng} and Kostya Ostrikov and {Ataur Rahman}, Md and Sharath Sriram",
year = "2018",
month = "1",
day = "1",
doi = "10.1063/1.5010158",
language = "English",
volume = "12",
journal = "Biomicrofluidics",
issn = "1932-1058",
publisher = "American Institute of Physics Publising LLC",
number = "1",

}

TY - JOUR

T1 - Dielectrophoresis-based microfluidic platforms for cancer diagnostics

AU - Chan, Jun Yuan

AU - Ahmad Kayani, Aminuddin Bin

AU - Md Ali, Mohd Anuar

AU - Kok, Chee Kuang

AU - Yeop Majlis, Burhanuddin

AU - Hoe, Susan Ling Ling

AU - Marzuki, Marini

AU - Khoo, Alan Soo Beng

AU - Ostrikov, Kostya

AU - Ataur Rahman, Md

AU - Sriram, Sharath

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The recent advancement of dielectrophoresis (DEP)-enabled microfluidic platforms is opening new opportunities for potential use in cancer disease diagnostics. DEP is advantageous because of its specificity, low cost, small sample volume requirement, and tuneable property for microfluidic platforms. These intrinsic advantages have made it especially suitable for developing microfluidic cancer diagnostic platforms. This review focuses on a comprehensive analysis of the recent developments of DEP enabled microfluidic platforms sorted according to the target cancer cell. Each study is critically analyzed, and the features of each platform, the performance, added functionality for clinical use, and the types of samples, used are discussed. We address the novelty of the techniques, strategies, and design configuration used in improving on existing technologies or previous studies. A summary of comparing the developmental extent of each study is made, and we conclude with a treatment of future trends and a brief summary.

AB - The recent advancement of dielectrophoresis (DEP)-enabled microfluidic platforms is opening new opportunities for potential use in cancer disease diagnostics. DEP is advantageous because of its specificity, low cost, small sample volume requirement, and tuneable property for microfluidic platforms. These intrinsic advantages have made it especially suitable for developing microfluidic cancer diagnostic platforms. This review focuses on a comprehensive analysis of the recent developments of DEP enabled microfluidic platforms sorted according to the target cancer cell. Each study is critically analyzed, and the features of each platform, the performance, added functionality for clinical use, and the types of samples, used are discussed. We address the novelty of the techniques, strategies, and design configuration used in improving on existing technologies or previous studies. A summary of comparing the developmental extent of each study is made, and we conclude with a treatment of future trends and a brief summary.

UR - http://www.scopus.com/inward/record.url?scp=85042697327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042697327&partnerID=8YFLogxK

U2 - 10.1063/1.5010158

DO - 10.1063/1.5010158

M3 - Article

AN - SCOPUS:85042697327

VL - 12

JO - Biomicrofluidics

JF - Biomicrofluidics

SN - 1932-1058

IS - 1

M1 - 011503

ER -